Gain Therapeutics, Inc.
corporate_fare Company Profile
Gain Therapeutics, Inc. (NASDAQ:GANX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for GANX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for GANX spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Gain Therapeutics 10-Q: Going Concern Warning With $11.7M Cash, Runway Into Q2 2027
- Rexaceract Shows 12-Month Motor Stability in Parkinson's, Phase 2 Set for 1Q27
- Gain Therapeutics Reports 12-Month Phase 1b Data Showing Motor Score Stabilization in Parkinson's
- Gain Therapeutics Q2 2026: Going Concern Warning, $13.1M Cash, and Ongoing ATM Dilution
- Gain Therapeutics Q2 2026: $13.1M Cash Provides Runway into Q2 2027 as Phase 2 Start Nears
Financial Snapshot
Short Interest & Short Volume
5.55 days to coverFINRA reported short interest of 3,891,227 shares in GANX as of the October 30, 2026 settlement, a 21.9% increase from the prior period — about 5.5 days to cover at its recent average daily volume. On November 20, 2026, 42.8% of GANX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.